No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Researchers find a master epigenetic switch that activates silenced genes to compensate for their missing counterparts in a ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

By activating a master epigenetic switch using CRISPR, naturally suppressed genes can be turned on, offering hope for Prader-Willi syndrome.

A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...